Search results for "Dication"

showing 10 items of 733 documents

Analysis of the Impact of Disease Acceptance, Demographic, and Clinical Variables on Adherence to Treatment Recommendations in Elderly Type 2 Diabete…

2021

This project aimed to analyze the impact of disease acceptance and selected demographic and clinical factors on the adherence to treatment recommendations in elderly type 2 diabetes mellitus patients. The observational study was performed using standardized research questionnaires: the Acceptance of Illness Scale (AIS), the Self-Care of Diabetes Inventory (SCODI), and the Adherence in Chronic Diseases Scale (ACDS). Two hundred patients with T2DM were studied (age M = 70.21 years, SD = 6.63 years). The median degree of disease acceptance was 29 (min–max = 8–40) and the median level of adherence was 24 (min–max = 13–28). Disease acceptance was a significant (p = 0.002) independent predictor o…

Biopsychosocial modelmedicine.medical_specialtytype 2 diabetes mellitusHealth Toxicology and MutagenesisPsychological interventionDiseasecomplianceArticleMedication AdherenceSurveys and QuestionnairesDiabetes mellitusInternal medicineHumansMedicineadherenceDemographyGlycemicbusiness.industryPublic Health Environmental and Occupational HealthRType 2 Diabetes Mellitusmedicine.diseaseSelf CareagedDiabetes Mellitus Type 2PillMedicineObservational studybusinessInternational Journal of Environmental Research and Public Health
researchProduct

Leukocyte–platelet aggregates—a phenotypic characterization of different stages of peripheral arterial disease

2016

The formation of monocyte-platelet aggregates and neutrophil-platelet aggregates (MPA and NPA, respectively) is influenced by inflammation, but also might contribute to an exacerbation of inflammatory responses in atherosclerotic plaque. The purpose of this study was to analyze MPA and NPA proportions in regard to different stages of peripheral arterial disease (PAD). Forty-five patients with intermittent claudication (IC) (3 groups: Rutherford (R)-1, R-2, and R-3; each n = 15), 20 patients with critical limb ischemia (CLI) (Rutherford 5 (40%) and 6 (60%)), and 20 healthy controls were studied. Analyses of monocyte (Mon) subpopulations (CD14++CD16- (classical) Mon1, CD14++CD16+ (intermediat…

Blood PlateletsMale0301 basic medicinemedicine.medical_specialtyNeutrophilsLipopolysaccharide ReceptorsInflammationComorbidity030204 cardiovascular system & hematologyFibrinogenMonocytesProinflammatory cytokinePeripheral Arterial Disease03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineLeukocytesmedicineHumansPlateletReceptors ImmunologicAgedCell AggregationWhole bloodAged 80 and overbusiness.industryMonocyteReceptors IgGHematologyGeneral MedicineCritical limb ischemiaMiddle AgedFlow CytometryIntermittent claudicationBlood Cell CountPhenotype030104 developmental biologyEndocrinologymedicine.anatomical_structureImmunologyFemalemedicine.symptombusinessCell Adhesion MoleculesBiomarkersmedicine.drugPlatelets
researchProduct

Plasma concentration following oral and intramuscular atropine in children and their clinical effects.

1997

In a paediatric population, we compared i.m. v oral atropine premedication to a control group without atropine and determined atropine plasma concentrations (APC). Forty-five children were randomly assigned to one of three groups. Group I received atropine, 20 micrograms.kg-1 i.m., 15 min prior to induction. Group II received atropine, 30 micrograms.kg-1 orally, group III received no atropine. APC (expressed as percent of muscarine-2 receptor subtype occupancy), heart rate, rectal temperature, and salivation were determined before atropine, and 15, 25, 45, 60, 90, 120 (no APC), and 150 min following atropine. Only 10-20% of the M2-cholinoceptors were occupied after oral atropine with a peak…

BradycardiaAtropineMalemedicine.medical_specialtyGroup iiAdministration OralMuscarinic AntagonistsInjections IntramuscularReceptor subtypeBody TemperatureHeart RateInternal medicineHeart rateMedicineHumansChildReceptor Muscarinic M2business.industryReceptors MuscarinicAtropineAnesthesiology and Pain MedicineEndocrinologyAnesthesiaChild PreschoolPediatrics Perinatology and Child HealthPlasma concentrationPremedicationFemalemedicine.symptombusinessSalivationPreanesthetic MedicationPaediatric populationmedicine.drugPaediatric anaesthesia
researchProduct

Sustained low-efficiency dialysis (SLED) for acute lithium intoxication

2008

Acute lithium intoxication may cause serious neurologic and cardiac manifestations, up to the patient's death. Owing to its low molecular weight, relatively small volume of distribution close to that of total body water, and its negligible protein binding, lithium can be efficiently removed by any extracorporeal modality of renal replacement therapy (RRT). However, the shift from the intracellular to the extracellular compartment, with the inherent rebound phenomenon after the end of RRT, might limit the efficacy of the conventional, short-lasting haemodialysis. There have been no published studies up to now concerning the use of sustained low-efficiency dialysis (SLED) in lithium intoxicat…

Bradycardiamedicine.medical_specialtyLithium (medication)medicine.medical_treatmentCase Reportchemistry.chemical_compoundOliguriamedicineRenal replacement therapyDialysisbipolar disorderTransplantationbusiness.industryLithium carbonateGastric lavagedrug toxicitypsychotropic drugsSurgerychemistrylithiumNephrologyAnesthesiadialysisHemodialysismedicine.symptombusinessmedicine.drugClinical Kidney Journal
researchProduct

Revendication. Obligation de revendiquer, Application, Biens incorporels, Brevet d'invention (oui)

1997

International audience; (Com. 22 oct. 1996, Marmeys c/ Charrière, ès qual.)

Brevet d'invention[SHS.DROIT]Humanities and Social Sciences/LawRevendication[SHS.DROIT] Humanities and Social Sciences/LawREDRESSEMENT ET LIQUIDATION JUDICIAIRESActifBien incorporel
researchProduct

CORPORATE VENTURE CAPITAL SYNDICATION STRATEGIES: A DYNAMIC NETWORK PERSPECTIVE

2018

Corporate Venture Capital (CVC) syndication is embraced by over 80% of corporates which co-investing the same startups with other corporates create a CVC syndication network. In this paper, we aim at exploring the evolutionary dynamics of the CVC syndication network. Specifically, we address this topic adopting two different perspectives. First, we investigate the architectural evolution of the CVC syndication network examining five dimensions that characterize the evolution of the network structure (i.e. degree distribution, connectivity, clustering, density and degree assortativity). In addition, we study how three network strategies (i.e. prominence, entrepreneurial and relational) evolv…

CVC syndication social network dynamic network architectural evolution network strategy evolution
researchProduct

Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma

2022

Background: Statins are widely used in an ageing population, including subjects with solid malignancies. However, no conclusive evidence is currently available on their potential influence on patients' outcome. We aimed to assess whether statin exposure affects the survival of patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.Patients and methods: Medical records of patients with documented mRCC treated with second- or third-line nivolumab were reviewed at ten institutions from Italy, Spain and the USA. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit. Univariate and multivariate analyses were used to e…

Cancer ResearchSurvivalTumour responseStatinRenal cell carcinomaProgression-Free SurvivalKidney NeoplasmsNivolumabTreatment OutcomeOncologyChild PreschoolHumansImmunotherapyHydroxymethylglutaryl-CoA Reductase InhibitorsConcomitant medicationsCarcinoma Renal CellRetrospective Studies
researchProduct

Trabectedin-Related Liver Toxicity in Soft Tissue Sarcoma Patients: Always a Good Reason to Discontinue the Treatment?

2014

ABSTRACT Aim: A transient increase in liver enzymes is a well described side effect developed by almost 40% of soft tissue sarcoma (STS) patients treated with trabectedin, often leading to treatment delays or discontinuation. We retrospectively analysed the correlation between trabectedin-related liver toxicity and treatment outcome. Methods: Data from a total of 113 patients receiving trabectedin administered at the dose of 1.5 mg/m2 iv 24 hours in 3 reference centers were evaluated. This exploratory analysis was performed to assess the impact of liver toxicity (grade 3-4 AST and ALT increases) on the trabectedin efficacy and outcome in STS patients. All the patients included had metastati…

Cancer Researchmedicine.medical_specialtyLiver toxicityAnthracyclineSide effectPopulationLiposarcomaGastroenterologyInternal medicinemedicineeducationTrabectedineducation.field_of_studybusiness.industrySoft tissue sarcomaHazard ratioHematologymedicine.diseaseSynovial sarcomaDiscontinuationSurgeryOncologyPremedicationSarcomabusinessmedicine.drugAnnals of Oncology
researchProduct

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI…

2021

ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses treatment adherence based on the 8-item Morisky Medication Adherence Scale (MMAS-8). Here, we present MMAS-8 results at week 24. Overall, 101 of 188 evaluable patients completed the questionnaire at every visit (full completers). Mean (±standard deviation) total MMAS-8 scores remained stable from week 4 to week 24 in the overall population (7.54 ± 0.77 and 7.67 ± 0.70, respectively) and full completers (7.53 ± 0.79 and 7.67 ± 0.73, respectively). Rates of low (MMAS-8 ˂6) or medium (MMAS-8 ≥ 6 to ˂8) adherence were 25–40% and 26–36%, respec…

Cancer Researchmedicine.medical_specialtyRuxolitinib8-item Morisky Medication Adherence ScalePsychometricsTreatment adherenceruxolitiniboral therapiesMedication AdherenceCohort StudiesTreatment complianceInternal medicineSurveys and QuestionnairesNitrilesmedicineHumansIn patientProspective StudiesProspective cohort studyMyelofibrosistreatment compliance8-item Morisky Medication Adherence Scale oral therapies ruxolitinib treatment compliance Adherencebusiness.industryHematologyJanus Kinase 1Janus Kinase 2Interim analysismedicine.disease8-item Morisky Medication Adherence Scale; Adherence; oral therapies; ruxolitinib; treatment compliancePyrimidinesOncologyAdherencePrimary MyelofibrosisPyrazolesObservational studybusinessmedicine.drugLeukemialymphoma
researchProduct

Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal re…

2014

Background The incidence of acute kidney injury (AKI) is estimated at 10 to 20% in patients admitted to intensive care units (ICU) and often requires renal replacement therapy (RRT). ICU mortality in AKI patients can exceed 50%. Venous catheters are the preferred vascular access method for AKI patients requiring RRT, but carry a risk of catheter thrombosis or infection. Catheter lock solutions are commonly used to prevent such complications. Heparin and citrate locks are both widely used for tunneled, long-term catheters, but few studies have compared citrate versus heparin for patients with short-term, non-tunneled catheters. We aim to compare citrate 4% catheter lock solution versus hepar…

Catheter Obstructionmedicine.medical_specialtyCatheterization Central VenousTime Factorsmedicine.medical_treatmentHemodialysis CatheterCatheter ObstructionMedicine (miscellaneous)urologic and male genital diseasesHospitals UniversityStudy ProtocolAcute renal failureClinical ProtocolsDouble-Blind MethodRenal DialysisCitrate lockIntensive careUpper Extremity Deep Vein ThrombosisProhibitinsmedicineCentral Venous CathetersHumansPharmacology (medical)Heparin lockRenal replacement therapyCitratesProspective StudiesContraindicationbusiness.industryHeparinAcute kidney injuryAnticoagulantsEquipment DesignAcute Kidney Injurymedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryCatheterIntensive Care UnitsTreatment OutcomeResearch DesignHemodialysisHemodialysisFranceCritically ill patientbusinessCatheter lockTrials
researchProduct